Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | HPGD | P15428 | 2/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | PDXK | O00764 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxine SCHEMBL17389113 | 0.98 | KDM4E (0.73) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL3506 | 0.87 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL30267871 | 0.87 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL30877002 | 0.87 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL2322958 | 0.87 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL42293 | 0.85 | KDM4E (0.96) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL15769549 | 0.85 | KDM4E (0.96) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL3640160 | 0.85 | HPGD (0.96) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL10659848 | 0.85 | HPGD (0.96) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL444525 | 0.85 | KDM4E (0.96) | KDM4EALDH1A1HPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11859180-B2 | Antisense oligonucleotide compositions | IONIS PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | claimed |
| US-20210079391-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | IONIS PHARMACEUTICALS INC (US) | 2021-03-18 | — | — | US | claimed |
| US-20170211062-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-27 | — | — | US | claimed |
| US-20160002624-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2016-01-07 | — | — | US | claimed |
| US-11859180-B2 | Antisense oligonucleotide compositions | IONIS PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20210079391-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | IONIS PHARMACEUTICALS INC (US) | 2021-03-18 | — | — | US | disclosed |
| US-20190316123-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | IONIS PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-10174318-B2 | Antisense oligonucleotide compositions | IONIS PHARMACEUTICALS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170211062-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20160002624-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11859180-B2 | Antisense oligonucleotide compositions | UPF1, SNRPA1, HNRNPA1 | KDM4E 3741/4885ALDH1A1 2215/4885HPGD 4847/4885 |
| US-20210079391-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | UPF1, SNRPA1, HNRNPA1 | KDM4E 3741/4885ALDH1A1 2215/4885HPGD 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.